1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
246.25 USD   -0.30%
04:10aAmgen says Lumakras plus immunotherapy for lung cancer needs further study
RE
08/05Pfizer in advanced talks to buy Global Blood Therapeutics for $5 bln - WSJ
RE
08/05WALL STREET STOCK EXCHANGE : Another case of good news is bad news
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen Inc. Reaffirms Revenue Guidance for the Year 2022

06/15/2022 | 01:40pm EDT

Amgen Inc. reaffirmed revenue guidance for the year 2022. The company reaffirmed going to 2022 revenue ranges despite by headwinds.


© S&P Capital IQ 2022
All news about AMGEN INC.
04:10aAmgen says Lumakras plus immunotherapy for lung cancer needs further study
RE
08/05Pfizer in advanced talks to buy Global Blood Therapeutics for $5 bln - WSJ
RE
08/05WALL STREET STOCK EXCHANGE : Another case of good news is bad news
MS
08/05Amgen reports second quarter 2022 financial results
AQ
08/05RBC Raises Price Target on Amgen to $236 From $224, Cites 'Another Quarter of Solid Exe..
MT
08/05Morgan Stanley Raises Price Target on Amgen to $257 From $253, Highlights 'Solid Beat' ..
MT
08/05Piper Sandler Adjusts Amgen's Price Target to $265 From $260, Reiterates Overweight Rat..
MT
08/05Amgen Signals Additional $100 Million Hit to Revenue From Foreign Exchange Following Vo..
MT
08/05MARKETSCREENER’S WORLD PRESS REVIEW : August 5, 2022
MS
08/05AMGEN INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF ..
AQ
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2022 26 188 M - -
Net income 2022 6 582 M - -
Net Debt 2022 27 064 M - -
P/E ratio 2022 20,2x
Yield 2022 3,09%
Capitalization 132 B 132 B -
EV / Sales 2022 6,06x
EV / Sales 2023 5,76x
Nbr of Employees 24 200
Free-Float 99,6%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 246,25 $
Average target price 247,76 $
Spread / Average Target 0,61%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.9.46%131 727
JOHNSON & JOHNSON0.02%449 879
ELI LILLY AND COMPANY9.09%286 307
PFIZER, INC.-15.56%276 449
ROCHE HOLDING AG-16.46%271 358
ABBVIE INC.2.60%244 068